From GlobeNewswire: 2025-05-27 09:30:00

The Global HLA Typing Market was valued at USD 1.62 billion in 2024 and is projected to grow at a CAGR of 6.58% to reach USD 2.69 billion by 2032. Key factors driving market demand include the need for precise donor-recipient matching in organ transplants and the rising incidence of autoimmune diseases and cancers.

In the US, the HLA typing market was valued at USD 0.64 billion in 2024 and is expected to reach USD 0.98 billion by 2032, driven by strong transplantation capabilities and increased interest in companion diagnostics for immunotherapy.

HLA typing plays a crucial role in organ and stem cell transplant matching systems. Advances in genomics and high-resolution typing systems have expanded market perspectives in clinical and research settings, with growing demand for fast and accurate diagnostics in precision medicine.

Apart from transplantation, HLA typing is also widely used in autoimmune disease diagnosis, pharmacogenomics, and drug development. Next-generation sequencing (NGS) technology has significantly improved the resolution and accuracy of HLA typing, making it essential for clinical and research applications.

In 2024, the HLA typing market was led by reagents and consumables, accounting for 62.2% of total revenue. The transplantation application remained the largest, but the diagnostic segment is expected to grow rapidly, driven by the recognition of HLA markers in autoimmune diseases.

The molecular technique dominated the market in 2024, accounting for 61.0% of revenue. Next-generation sequencing (NGS) is becoming the preferred method due to its high-resolution genotyping capabilities. Transplant centers and hospitals were the largest end-users, while research labs and academic institutes are expected to grow rapidly.

North America led the HLA typing market in 2024, driven by established healthcare infrastructure and high transplant procedures. The Asia-Pacific market is experiencing the highest growth, with increased awareness of organ donations and investments in genomics driving regional expansion.

Recent developments include new products from Thermo Fisher Scientific, CareDx, and Immucor aimed at enhancing HLA typing accuracy and efficiency. The global number of solid organ transplants exceeded 160,000 in 2023, with kidney and liver transplants comprising over 75% of procedures.

Between 2020 and 2023, over 1,200 new molecular diagnostic labs with HLA typing systems were established worldwide, indicating the growing importance of HLA typing in healthcare. The HLA typing market is expected to double by 2032, with 52% of testing costs covered by government health plans in the U.S. Over 60% of transplant centers globally now use genetic sequencing data for donor matching and graft rejection risk assessment, indicating a shift towards personalized transplantation protocols.

For more detailed insights and analysis, you can purchase a Single-User PDF of the HLA Typing Market Analysis & Outlook Report 2024-2032 at https://www.snsinsider.com/checkout/3176. The report covers key points such as market dynamics impact analysis, statistical insights, competitive landscape, regional analysis, and more.

In related news, the immunology market is expected to reach $254.23 billion by 2032 with an 11.8% CAGR, while the U.S. clinical laboratory services market is projected to hit $95.15 billion by 2032 growing at a 3.65% CAGR. Additionally, the stem cell therapy market is forecasted to reach $1.11 billion by 2032 with a 17.1% CAGR, and the global genetic testing market is set to triple by 2032, reaching $46.29 billion with an 11.34% CAGR.

SNS Insider is a leading market research and consulting agency providing clients with current, accurate market data and consumer insights to make informed decisions in changing circumstances. Utilizing various techniques such as surveys, video talks, and focus groups globally, we aim to empower our clients with the knowledge they need to thrive in the market.



Read more at GlobeNewswire: HLA Typing Market is Projected to Reach by USD 2.69 Billion